Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quinacrine · 1 trial · 1 indication
Patients who achieved a complete response (CR) or a partial response (PR) to therapy were allowed to continue to receive treatment until disease progression or unacceptable toxicity occurred, until the patient discontinued treatment for another reason, or for a total of 6 months. Patients who continued to show a CR or PR or who maintained stable disease (SD) after 6 months of therapy were to be allowed to continue therapy at the investigator's discretion.
| Arm | Type | Description |
|---|---|---|
| Quinacrine | EXPERIMENTAL | Uncontrolled treatment arm |
| Name | Type | Description |
|---|---|---|
| Quinacrine | DRUG | 100 mg daily |
Inclusion Criteria: * Patients must be males, at least 18 years of age, with pathologically confirmed adenocarcinoma of the prostate * Patients must have evidence of androgen-independent metastatic prostate cancer (AIMPC) following standard antiandrogen withdrawal. AIMPC will be defined as the cate...